Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
About this item
Full title
Author / Creator
SUSTAIN-6 Investigators , Marso, Steven P , Bain, Stephen C , Consoli, Agostino , Eliaschewitz, Freddy G , Jódar, Esteban , Leiter, Lawrence A , Lingvay, Ildiko , Rosenstock, Julio , Seufert, Jochen , Warren, Mark L , Woo, Vincent , Hansen, Oluf , Holst, Anders G , Pettersson, Jonas and Vilsbøll, Tina
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with type 2 diabetes at high cardiovascular risk received either once-weekly semaglutide, a glucagon-like peptide 1 analogue, or placebo. The rate of a first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke was significantly lower with semaglutide.
Cardiovascular disease is the leading cause of death and complications...
Alternative Titles
Full title
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1838248901
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1838248901
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1607141
